Acute Chest Syndrome in Children with Sickle Cell Disease
Open Access
- 1 December 2017
- journal article
- review article
- Published by Mary Ann Liebert Inc in Pediatric Allergy, Immunology, and Pulmonology
- Vol. 30 (4), 191-201
- https://doi.org/10.1089/ped.2017.0814
Abstract
Acute chest syndrome (ACS) is a frequent cause of acute lung disease in children with sickle cell disease (SCD). Patients may present with ACS or may develop this complication during the course of a hospitalization for acute vaso-occlusive crises (VOC). ACS is associated with prolonged hospitalization, increased risk of respiratory failure, and the potential for developing chronic lung disease. ACS in SCD is defined as the presence of fever and/or new respiratory symptoms accompanied by the presence of a new pulmonary infiltrate on chest X-ray. The spectrum of clinical manifestations can range from mild respiratory illness to acute respiratory distress syndrome. The presence of severe hypoxemia is a useful predictor of severity and outcome. The etiology of ACS is often multifactorial. One of the proposed mechanisms involves increased adhesion of sickle red cells to pulmonary microvasculature in the presence of hypoxia. Other commonly associated etiologies include infection, pulmonary fat embolism, and infarction. Infection is a common cause in children, whereas adults usually present with pain crises. Several risk factors have been identified in children to be associated with increased incidence of ACS. These include younger age, severe SCD genotypes (SS or Sβ0 thalassemia), lower fetal hemoglobin concentrations, higher steady-state hemoglobin levels, higher steady-state white blood cell counts, history of asthma, and tobacco smoke exposure. Opiate overdose and resulting hypoventilation can also trigger ACS. Prompt diagnosis and management with intravenous fluids, analgesics, aggressive incentive spirometry, supplemental oxygen or respiratory support, antibiotics, and transfusion therapy, are key to the prevention of clinical deterioration. Bronchodilators should be considered if there is history of asthma or in the presence of acute bronchospasm. Treatment with hydroxyurea should be considered for prevention of recurrent episodes. This review evaluates the etiology, pathophysiology, risk factors, clinical presentation of ACS, and preventive and treatment strategies for effective management of ACS.Keywords
This publication has 141 references indexed in Scilit:
- Extracellular hemin crisis triggers acute chest syndrome in sickle miceJCI Insight, 2013
- Risk Factors for Increased ED Utilization in a Multinational Cohort of Children With Sickle Cell DiseaseAcademic Emergency Medicine, 2012
- Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE)British Journal of Haematology, 2012
- Pulmonary embolism in sickle cell disease: a case–control studyJournal of Thrombosis and Haemostasis, 2012
- Elevation of IgE in children with sickle cell disease is associated with doctor diagnosis of asthma and increased morbidityJournal of Allergy and Clinical Immunology, 2011
- Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain CrisisJama-Journal Of The American Medical Association, 2011
- Multi‐modal intervention for the inpatient management of sickle cell pain significantly decreases the rate of acute chest syndromePediatric Blood & Cancer, 2010
- Multi‐modal intervention and prospective implementation of standardized sickle cell pain admission orders reduces 30‐day readmission ratePediatric Blood & Cancer, 2009
- Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell diseasePediatric Blood & Cancer, 2007
- Painful Episodes in Children With Sickle Cell Disease and Asthma are Temporally Associated With Respiratory SymptomsJournal of Pediatric Hematology/Oncology, 2006